Summary
Hypertension is a common disorder that affects a large proportion of the community. It is usually asymptomatic and is detected on routine exam or after the occurrence of a complication such as a heart attack or stroke.[1]Lip GY. Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension. 2003 Feb;41(2):199-200. http://hyper.ahajournals.org/cgi/content/full/41/2/199 http://www.ncbi.nlm.nih.gov/pubmed/12574081?tool=bestpractice.com
Hypertension has been defined in joint guidelines by American learned bodies (American College of Cardiology [ACC] and American Heart Association [AHA] among others) and also by the British Society of Hypertension and the European Society of Hypertension.[2]Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018 May 15;71(19):e127-248. http://www.ncbi.nlm.nih.gov/pubmed/29146535?tool=bestpractice.com [3]Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139-85. https://www.nature.com/articles/1001683 http://www.ncbi.nlm.nih.gov/pubmed/14973512?tool=bestpractice.com [4]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. https://academic.oup.com/eurheartj/article/39/33/3021/5079119 http://www.ncbi.nlm.nih.gov/pubmed/30165516?tool=bestpractice.com There are differences in the definition of hypertension between guidelines.
The 2017 ACC/AHA guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults defines hypertension as any systolic blood pressure measurement of ≥130 mmHg or any diastolic blood pressure measurement of ≥80 mmHg.[2]Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018 May 15;71(19):e127-248. http://www.ncbi.nlm.nih.gov/pubmed/29146535?tool=bestpractice.com ACC/AHA blood pressure categories are defined as follows:
Elevated blood pressure: systolic blood pressure of 120-129 mmHg and diastolic blood pressure of <80 mmHg
Stage 1 hypertension: systolic blood pressure of 130-139 mmHg and/or diastolic blood pressure of 80-89 mmHg
Stage 2 hypertension: systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg.
The 2017 ACC/AHA guidelines definition represents a more aggressive approach to diagnosis and treatment of hypertension compared with Joint National Committee (JNC) 7 and JNC 8 recommendations, where blood pressure in the range of 120-139 mmHg/80-89 mmHg is considered prehypertension and blood pressure >140/90 mmHg is considered elevated.[5]Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. http://www.ncbi.nlm.nih.gov/pubmed/12748199?tool=bestpractice.com [6]James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20. http://jama.jamanetwork.com/article.aspx?articleid=1791497 http://www.ncbi.nlm.nih.gov/pubmed/24352797?tool=bestpractice.com
Publication of the 2017 ACC/AHA guidelines has prompted widespread debate, and there are calls for the recommendations to be revisited. Implementing the guidelines would increase the prevalence of hypertension by 26.8% in the US. Critics are concerned that labelling more patients as hypertensive could increase psychological morbidity, as well as exposing lower-risk patients to the potential harm of antihypertensive medications.[7]Khera R, Lu Y, Lu J, et al. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. BMJ. 2018 Jul 11;362:k2357. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039831 http://www.ncbi.nlm.nih.gov/pubmed/29997129?tool=bestpractice.com
The 2017 ACC/AHA guidelines were mainly based on the results of the SPRINT trial, which investigated intensive or standard hypertension treatment in people with a systolic blood pressure of ≥130 mmHg with an increased cardiovascular risk (but without diabetes).[8]SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16. https://www.nejm.org/doi/10.1056/NEJMoa1511939 http://www.ncbi.nlm.nih.gov/pubmed/26551272?tool=bestpractice.com Listen to our podcast for more on the controversy. BMJ Best Practice Podcast: hypertension Opens in new window
European guidelines categorize hypertension as follows:[4]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. https://academic.oup.com/eurheartj/article/39/33/3021/5079119 http://www.ncbi.nlm.nih.gov/pubmed/30165516?tool=bestpractice.com
High-normal: systolic 130-139 mmHg and/or diastolic 85-89 mmHg
Grade 1: systolic 140-159 mmHg and/or diastolic 90-99 mmHg
Grade 2: systolic 160-179 mmHg and/or diastolic 100-109 mmHg
Grade 3: systolic ≥180 mmHg and/or diastolic ≥110 mmHg.
Isolated systolic hypertension is also graded according to systolic blood pressure values in the ranges indicated, provided that diastolic values are <90 mmHg.[4]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. https://academic.oup.com/eurheartj/article/39/33/3021/5079119 http://www.ncbi.nlm.nih.gov/pubmed/30165516?tool=bestpractice.com
Although different studies have used a variety of cut-off points for the diagnosis of hypertension in the community, any blood pressure >120 mmHg systolic is associated with an increased cardiovascular risk. The importance of hypertension is its relation to other cardiovascular risk factors and consequent overall cardiovascular risk.
The AHA defines resistant hypertension as:[9]Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90. https://www.ahajournals.org/doi/full/10.1161/HYP.0000000000000084 http://www.ncbi.nlm.nih.gov/pubmed/30354828?tool=bestpractice.com
Clinic blood pressure >130/80 mmHg despite the concurrent use of at least 3 antihypertensive agents (including an ACE inhibitor or angiotensin receptor antagonist, a long-acting calcium channel blocker, and a diuretic) at maximum or maximally tolerated doses.
Patients who require 4 or more antihypertensive agents to achieve their target blood pressure are also considered to have resistant hypertension. The diagnosis requires the exclusion of white-coat hypertension and poor adherence with antihypertensive medication.
This topic addresses the evaluation of hypertension in adults.
Epidemiology
Based on National Health and Nutrition Survey (NHANES) data from 2013 to 2016, an estimated 116.4 million US adults ages ≥20 years have hypertension (cut-off value 140/90 mmHg).[10]Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. https://www.doi.org/10.1161/CIR.0000000000000757 http://www.ncbi.nlm.nih.gov/pubmed/31992061?tool=bestpractice.com During this period, the prevalence of hypertension was 26.1% among those ages 20-44 years, 59.2% among those ages 45-64 years, and 78.2% among those ages ≥65 years.[10]Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. https://www.doi.org/10.1161/CIR.0000000000000757 http://www.ncbi.nlm.nih.gov/pubmed/31992061?tool=bestpractice.com The prevalence may be similar or higher in Western Europe.[11]Falaschetti E, Mindell J, Knott C, et al. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014 May 31;383(9932):1912-9. http://www.ncbi.nlm.nih.gov/pubmed/24881995?tool=bestpractice.com [12]Lacruz ME, Kluttig A, Hartwig S, et al. Prevalence and incidence of hypertension in the general adult population: results of the CARLA-cohort study. Medicine (Baltimore). 2015 Jun;94(22):e952. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616348 http://www.ncbi.nlm.nih.gov/pubmed/26039136?tool=bestpractice.com
Globally, the overall prevalence of hypertension in adults is 30% to 45%, according to European guidelines, with a higher prevalence in men than in women (24% and 20%, respectively).[4]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. https://academic.oup.com/eurheartj/article/39/33/3021/5079119 http://www.ncbi.nlm.nih.gov/pubmed/30165516?tool=bestpractice.com
Hypertension is more prevalent in black people than in white people, starting in childhood, with 76% of black men and women developing hypertension by age 55 years, compared with 55% and 40% of white men and women, respectively.[13]Thomas SJ, Booth JN 3rd, Dai C, et al. Cumulative incidence of hypertension by 55 years of age in blacks and whites: the CARDIA study. J Am Heart Assoc. 2018 Jul 11;7(14). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064834 http://www.ncbi.nlm.nih.gov/pubmed/29997132?tool=bestpractice.com
The exact prevalence of hypertension is difficult to assess, as it is usually asymptomatic. Prevalence is expected to rise as the "cut-off" value for hypertension is redefined at a lower level.
Approximately 15% of patients with hypertension have resistant hypertension.[9]Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90. https://www.ahajournals.org/doi/full/10.1161/HYP.0000000000000084 http://www.ncbi.nlm.nih.gov/pubmed/30354828?tool=bestpractice.com
Complications and hypertension-mediated organ damage
Studies have shown that treatment of hypertension can reduce the incidence of future cardiovascular and cerebrovascular events.[14]Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000 Feb;35(2):539-43. http://hyper.ahajournals.org/cgi/content/full/35/2/539 http://www.ncbi.nlm.nih.gov/pubmed/10679494?tool=bestpractice.com The aim of early diagnosis and treatment of hypertension is to lower overall cardiovascular risk and prevent cerebrovascular events.
The effects of chronic hypertension on organ systems are referred to as hypertension-mediated organ damage.
Left ventricular hypertrophy, cardiovascular disease, cerebrovascular disease, hypertensive retinopathy, and nephropathy are the most common manifestations.[15]Nadar SK, Tayebjee MH, Meserelli F, et al. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des. 2006;12(13):1581-92. http://www.ncbi.nlm.nih.gov/pubmed/16729871?tool=bestpractice.com The presence of left ventricular hypertrophy is a poor prognostic sign, and regression of left ventricular hypertrophy improves prognosis.[16]Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. http://www.ncbi.nlm.nih.gov/pubmed/12493255?tool=bestpractice.com Patients with resistant hypertension are at higher risk of experiencing cardiovascular and cerebrovascular events and developing chronic kidney disease.[9]Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90. https://www.ahajournals.org/doi/full/10.1161/HYP.0000000000000084 http://www.ncbi.nlm.nih.gov/pubmed/30354828?tool=bestpractice.com
Cardiovascular risk
Guidelines on the management of hypertension emphasize the importance of calculating and managing the overall cardiovascular risk of a patient, rather than focusing only on blood pressure readings. The ACC and AHA have published an online tool to calculate patients’ 10-year and lifetime risk of atherosclerotic cardiovascular disease. ACC: ASCVD Risk Estimator Plus Opens in new window For individuals ages 40-70 years, each increment of 20 mmHg in systolic blood pressure or 10 mmHg in diastolic blood pressure across the entire blood pressure range from 115/75 to 185/115 mmHg doubles the risk of cardiovascular disease.[17]Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1984 Jul 27;252(4):487-90. http://www.ncbi.nlm.nih.gov/pubmed/6737638?tool=bestpractice.com Treating associated cardiovascular risk factors such as obesity, diabetes, hypercholesterolemia, and smoking are as important as managing hypertension in lowering overall cardiovascular risk.
Meta-analysis has confirmed that lowering blood pressure reduces cardiovascular disease and death in people with baseline systolic blood pressure of 140 mmHg or higher.[18]Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28-36. http://www.ncbi.nlm.nih.gov/pubmed/29131895?tool=bestpractice.com However, primary preventive blood pressure lowering does not benefit people with lower baseline blood pressure (except those with preexisting cardiovascular disease).[18]Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28-36. http://www.ncbi.nlm.nih.gov/pubmed/29131895?tool=bestpractice.com One Cochrane review found insufficient evidence to justify lower blood pressure targets (≤135/85 mmHg) in people with hypertension and cardiovascular disease.[19]Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2018 Jul 20;(7):CD010315. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010315.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/30027631?tool=bestpractice.com
Differentials
Common
- Essential hypertension
- Renal artery stenosis
- Chronic kidney disease
- Obstructive uropathy
- Obstructive sleep apnea/hypopnea syndrome
- Obesity hypoventilation syndrome
Uncommon
- Coarctation of aorta
- Preeclampsia
- Glomerulonephritis
- Nephrotic syndrome
- Polycystic kidney disease
- Pheochromocytoma
- Hyperaldosteronism
- Cushing disease/syndrome
- Hyperthyroidism
- Hypothyroidism
- Hyperparathyroidism
- Chronic alcohol excess
- Medication
- Illicit drug use
- "White-coat hypertension"
Contributors
Authors
Sunil Nadar, MD, FRCP, CCT, FESC
Senior Consultant Cardiologist
Sultan Qaboos University Hospital
Muscat
Oman
Disclosures
SN is an author of a number of references cited in this topic.
Gregory Y.H. Lip, MD, FRCP, DFM, FACC, FESC, FEHRA
Price-Evans Professor of Cardiovascular Medicine
University of Liverpool
Senior Investigator
National Institute for Health Research
UK
Distinguished Professor
Faculty of Medicine
Aalborg University
Denmark
Adjunct Professor
Yonsei University
Seoul
South Korea
Disclosures
GYHL is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo; he is also a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. GYHL is an author of a number of references cited in this topic.
Peer reviewers
Rod Jackson, MD, PhD
Professor of Epidemiology
Head of the Section of Epidemiology & Biostatistics
School of Population Health
University of Auckland
Auckland
New Zealand
Disclosures
RJ declares that he has no competing interests.
Alan Wilkinson, MD, FRCP
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles
CA
Disclosures
AW declares that he has no competing interests. Unfortunately we have since been made aware that Professor Wilkinson is deceased.
Michael Schachter, MB, BSc, FRCP
Department of Clinical Pharmacology
St Mary’s Hospital
Imperial College
London
UK
Disclosures
MS declares that he has no competing interests.
Patient leaflets
Heart attack
High blood pressure
More Patient leafletsCalculators
Epworth Sleepiness Scale (ESS)
More CalculatorsVideos
Venepuncture and phlebotomy: animated demonstration
How to perform an ECG: animated demonstration
More videosLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer